Sugi Predict

Sugi Predict / Targets / AEBP2

AEBP2

Zinc finger protein AEBP2 (Adipocyte enhancer · Q6ZN18 · AEBP2 on Sugi Atlas →

13,889 patent compounds predicted against AEBP2, 9,863 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9286474 SCHEMBL9286474 0.54 14/20
SCHEMBL9887622 SCHEMBL9887622 0.57 10/20
SCHEMBL9277204 SCHEMBL9277204 0.56 9/20
SCHEMBL9280924 SCHEMBL9280924 0.53 9/20
SCHEMBL9280875 SCHEMBL9280875 0.48 8/20
SCHEMBL989559 SCHEMBL989559 0.32 8/20
SCHEMBL9284791 SCHEMBL9284791 0.64 7/20
SCHEMBL2586392 SCHEMBL2586392 0.54 7/20
SCHEMBL9277210 SCHEMBL9277210 0.54 7/20
SCHEMBL2593063 SCHEMBL2593063 0.53 7/20
SCHEMBL9281286 SCHEMBL9281286 0.50 7/20
SCHEMBL9277387 SCHEMBL9277387 0.59 6/20
SCHEMBL2594034 SCHEMBL2594034 0.49 6/20
SCHEMBL2593163 SCHEMBL2593163 0.48 6/20
SCHEMBL9279859 SCHEMBL9279859 0.48 6/20
SCHEMBL2594666 SCHEMBL2594666 0.47 6/20
SCHEMBL1695610 SCHEMBL1695610 0.47 6/20
SCHEMBL2589109 SCHEMBL2589109 0.65 5/20
SCHEMBL9285070 SCHEMBL9285070 0.62 5/20
SCHEMBL2586263 SCHEMBL2586263 0.62 5/20

Clinical trials — most relevant to AEBP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients PHASE3COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer PHASE1COMPLETED
Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults PHASE1COMPLETED
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B) nanCOMPLETED
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
Biomarkers in Idiopathic Juvenile Arthritis nanUNKNOWN
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) nanUNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia nanUNKNOWN
Linkage Study in Familial Pulmonary Fibrosis nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients nanRECRUITING
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia nanACTIVE_NOT_RECRUITING
Genetic Analysis of Hereditary Disorders of Hearing and Balance nanCOMPLETED
Hemochromatosis and Iron Overload Screening Study (HEIRS) nanCOMPLETED
Biomarker in Tissue Samples From Patients With Ewing Sarcoma nanCOMPLETED
Long Term Prediction of MASH-related HCC Risk by Proteomics nanNOT_YET_RECRUITING
MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma nanUNKNOWN
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma nanCOMPLETED
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Identification of Biomarkers for Early Detection of Pancreatic Cancer nanCOMPLETED
Exome Analysis in Hearing Impaired Patients nanUNKNOWN
Expression and Clinical Significance of IGHD in Pancreatic Cancer nanUNKNOWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Genetics and Psychopathology in the 22q11 Deletion Syndrome nanUNKNOWN
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AEBP2 binder may also engage these)

ProteinNameSimilarity
A4FV57 — 1.000 A4FV57 →
Q9Z248 — 0.999 Q9Z248 →
Q7SXV2 — 0.985 Q7SXV2 →
Q6GR30 — 0.982 Q6GR30 →
P49797 — 0.965 P49797 →
Q5RDF5 — 0.963 Q5RDF5 →
P0C6S7 — 0.962 P0C6S7 →
Q80ZQ5 — 0.962 Q80ZQ5 →
Q8R3B7 — 0.962 Q8R3B7 →
Q8CE64 — 0.962 Q8CE64 →
Q8BIZ1 — 0.961 Q8BIZ1 →
Q03355 — 0.960 Q03355 →
Q7Z6G8 — 0.960 Q7Z6G8 →
Q03353 — 0.960 Q03353 →
Q8BIE6 — 0.960 Q8BIE6 →
Q3UR85 — 0.959 Q3UR85 →
BCR Breakpoint cluster region protein 0.959 landscape →
Q5T6S3 — 0.959 Q5T6S3 →
Q8N108 — 0.959 Q8N108 →
Q9WU42 — 0.958 Q9WU42 →
Q5REE1 — 0.958 Q5REE1 →
O09112 — 0.958 O09112 →
Q86VZ6 — 0.958 Q86VZ6 →
O00287 — 0.957 O00287 →
Q8WXG6 — 0.957 Q8WXG6 →
Q14CM0 — 0.957 Q14CM0 →
Q80U28 — 0.957 Q80U28 →
NCOR2 Nuclear receptor corepressor 2 0.957 landscape →
Q99NA9 — 0.957 Q99NA9 →
Q9Z272 — 0.957 Q9Z272 →